#co-pay

The ruling centered on PrEP as HIV prevention but could apply to cancer screenings and other services and drugs.

Insurers should allow co-pay assistance to count as out-of-pocket spending, claims HHS lawsuit by HIV, hepatitis and diabetes advocates.

Some 100 million people—including 41% of U.S. adults—have health care debt, according to a recent KFF survey.

A letter from 124 patient groups urges the White House to make drugs more affordable—and spells out how it can do so.

During the COVID-19 crisis, some insurers are relaxing their refill rules and allowing 90-day supplies of meds to be prescribed.

Over 60 drugmakers raised prices an average of 5.8% on hundreds of drugs.

Insurance companies can no longer implement harmful co-pay accumulator policies.

A look at the supply chain that results in very high costs for HIV and hepatitis C medications.

Stop me if you’ve heard this one before.

The patient advocacy coalition I Am Essential sent a letter to the HHS spelling out why the plan is dangerous.

Health coalition warns the federal government: People with chronic or serious conditions face growing costs at the pharmacy.

60 groups sign a letter to state insurance commissioners and attorneys general asking them to reverse the policy.

Cost concerns have led many private insurers and public payers to impose restrictions on treatment.